Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
Crossref DOI link: https://doi.org/10.1186/s13561-015-0066-2
Published Online: 2015-10-16
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sánchez-de la Rosa, Rainel
García-Bujalance, Laura
Meca-Lallana, José
Funding for this research was provided by:
Teva Pharmaceutical Industries
Text and Data Mining valid from 2015-10-16
Article History
Received: 26 February 2015
Accepted: 8 October 2015
First Online: 16 October 2015